EC Number | Application | Comment | Organism |
---|---|---|---|
2.3.1.68 | medicine | GLYATL1 is overexpressed in primary prostate cancer compared with metastatic prostate cancer and benign prostatic tissue. Low-grade cancers have higher GLYATL1 expression compared to high-grade prostate tumors. GLYATL1 is upregulated upon androgen treatment in LNCaP prostate cancer cells which harbor ETV1 gene rearrangement. ETV1 knockdown in LNCaP cells shows downregulation of GLYATL1 | Homo sapiens |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.13 | acyl-CoA + glycine | Homo sapiens | - |
CoA + N-acylglycine | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.3.1.13 | Homo sapiens | - |
- |
- |
2.3.1.68 | Homo sapiens | Q969I3 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.3.1.13 | CWR22-Rv1 cell | - |
Homo sapiens | - |
2.3.1.13 | DU-145 cell | - |
Homo sapiens | - |
2.3.1.13 | LNCaP cell | - |
Homo sapiens | - |
2.3.1.13 | LNCAP-C4-2B cell | - |
Homo sapiens | - |
2.3.1.13 | PC-3 cell | - |
Homo sapiens | - |
2.3.1.13 | prostate gland cancer cell | - |
Homo sapiens | - |
2.3.1.13 | RWPE-1 cell | - |
Homo sapiens | - |
2.3.1.13 | VCaP cell | - |
Homo sapiens | - |
2.3.1.68 | LNCaP cell | - |
Homo sapiens | - |
2.3.1.68 | prostate gland | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.13 | acyl-CoA + glycine | - |
Homo sapiens | CoA + N-acylglycine | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.3.1.13 | GLYATL1 | - |
Homo sapiens |
2.3.1.13 | glycine-N-acyltransferase like 1 | - |
Homo sapiens |
2.3.1.68 | GLYATL! | - |
Homo sapiens |
EC Number | Organism | Comment | Expression |
---|---|---|---|
2.3.1.13 | Homo sapiens | the enzyme is overexpressed in primary prostate cancer compared with metastatic prostate cancer and benign prostatic tissue. Low-grade cancers have higher enzyme expression compared to high-grade prostate tumors | up |